Praxis Precision Medicines Provides Vormatrigine Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
- Serbia's Vucic concedes defeat to student led movement in parliamentary election
Raymond James sees a 'unique buying opportunity' in this stock
June 2, 2026 4:00 PM EDTRaymond James believes the recent selloff in one biopharmaceutical companys shares has created an attractive entry point for investors, arguing that disappointment surrounding the company's vormatrigine program does not alter its core investment thesis.
In a research note, Raymond James analyst Tiago Fauth reiterated a Strong Buy rating on Praxis Precision Medicines (NASDAQ: PRAX) and maintained a Strong Buy rating despite a failed... More



